Masso Torrence Wealth Management Inc. Sells 6,060 Shares of Pfizer Inc. (NYSE:PFE)

Masso Torrence Wealth Management Inc. lowered its stake in shares of Pfizer Inc. (NYSE:PFE) by 41.4% during the 4th quarter, HoldingsChannel reports. The fund owned 8,583 shares of the biopharmaceutical company’s stock after selling 6,060 shares during the period. Masso Torrence Wealth Management Inc.’s holdings in Pfizer were worth $228,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also recently made changes to their positions in PFE. Hantz Financial Services Inc. grew its holdings in Pfizer by 34.5% during the 4th quarter. Hantz Financial Services Inc. now owns 514,184 shares of the biopharmaceutical company’s stock valued at $13,641,000 after buying an additional 131,760 shares in the last quarter. Foster Victor Wealth Advisors LLC grew its stake in Pfizer by 24.9% during the fourth quarter. Foster Victor Wealth Advisors LLC now owns 564,035 shares of the biopharmaceutical company’s stock valued at $14,834,000 after acquiring an additional 112,616 shares in the last quarter. Robeco Institutional Asset Management B.V. boosted its holdings in Pfizer by 41.8% in the 4th quarter. Robeco Institutional Asset Management B.V. now owns 6,377,817 shares of the biopharmaceutical company’s stock valued at $169,203,000 after purchasing an additional 1,879,504 shares during the period. Asset Dedication LLC increased its holdings in shares of Pfizer by 107.4% in the fourth quarter. Asset Dedication LLC now owns 26,833 shares of the biopharmaceutical company’s stock worth $712,000 after purchasing an additional 13,896 shares during the period. Finally, BSW Wealth Partners increased its holdings in shares of Pfizer by 2.1% in the fourth quarter. BSW Wealth Partners now owns 52,935 shares of the biopharmaceutical company’s stock worth $1,404,000 after purchasing an additional 1,111 shares during the period. 68.36% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

PFE has been the topic of several recent analyst reports. Wolfe Research started coverage on Pfizer in a report on Friday, November 15th. They issued an “underperform” rating and a $25.00 price target on the stock. Evercore ISI upgraded shares of Pfizer to a “strong-buy” rating in a research report on Wednesday, October 30th. Sanford C. Bernstein initiated coverage on shares of Pfizer in a research report on Thursday, October 17th. They set a “market perform” rating and a $32.00 target price for the company. Truist Financial decreased their price target on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a report on Wednesday, December 18th. Finally, UBS Group dropped their price objective on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a report on Wednesday, January 8th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, six have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $31.92.

Pfizer Stock Up 0.1 %

Shares of Pfizer stock opened at $26.79 on Wednesday. The stock has a market capitalization of $151.79 billion, a price-to-earnings ratio of 36.23, a P/E/G ratio of 0.64 and a beta of 0.64. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The company’s 50 day moving average price is $26.18 and its 200-day moving average price is $27.91. Pfizer Inc. has a 52-week low of $24.48 and a 52-week high of $31.54.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.64 by $0.42. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The company had revenue of $17.70 billion for the quarter, compared to analysts’ expectations of $14.92 billion. During the same period last year, the firm earned ($0.17) earnings per share. Pfizer’s quarterly revenue was up 31.2% on a year-over-year basis. Equities research analysts forecast that Pfizer Inc. will post 2.94 EPS for the current year.

Pfizer Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be issued a $0.43 dividend. The ex-dividend date is Friday, January 24th. This represents a $1.72 annualized dividend and a yield of 6.42%. This is a boost from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s payout ratio is 227.03%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.